Medexus to Present at the Winter Wonderland Conference- Best Ideas from the Buy-Side
- Wall Street ends week positively; S&P 500, Dow hit record highs
- Bitcoin (BTC) Drops 3% as Turkey Bans Cryptocurrency Payments Citing Lack of Regulatory Supervision
- Morgan Stanley (MS) Archegos-Related Loss Appears to be $911M
- Dollar at 4-week low on retreating Treasury yields
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
TORONTO, CHICAGO and MONTREAL, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it will be presenting at the Winter Wonderland Conference, hosted by The MicroCap Rodeo, being held virtually on February 16th – February 19th, 2021.
Ken d’Entremont, Chief Executive Officer and Roland Boivin, Chief Financial Officer of Medexus, are scheduled to present on Wednesday, February 17, 2021 at 9:30 AM, Eastern Time. The presentation will be webcast live and available for replay here. One-on-one meetings will be held throughout the conference via video conference calls.
About Medexus Pharmaceuticals Inc.
Medexus is a leading innovative and rare disease company with a strong North American commercial platform. From a foundation of proven best in class products we are building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin our growth for the next decade. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology, and allergy. The Company’s leading products are: Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall®, an innovative prescription allergy medication with a unique mode of action.
For more information, please contact:
Ken d’Entremont, Chief Executive OfficerMedexus Pharmaceuticals Inc.Tel.: 905-676-0003E-mail: firstname.lastname@example.org
Roland Boivin, Chief Financial OfficerMedexus Pharmaceuticals Inc.Tel.: 514-344-8765E-mail: email@example.com
Investor Relations (U.S.):Crescendo Communications, LLCTel: +1-212-671-1020Email: firstname.lastname@example.org
Investor Relations (Canada):Tina ByersAdelaide Capital Tel: 905-330-3275E-mail: email@example.com Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- The Malouf Foundation Hosts Successful Inaugural Trafficking Policy and Education Summit
- Introducing “Got Your Back,” A Lilly Pulitzer Print with Purpose in support of Baby2Baby
- Photo Release — Huntington Ingalls Industries Celebrates 154 Graduates of The Apprentice School at Newport News Shipbuilding in Drive-in Theater-style Ceremony